Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial

Sharif, Hanisah; Singh, Iesha; Kouser, Lubna; Mösges, Ralph; Bonny, Marie-Alix; Karamani, Angeliki; Parkin, Rebecca; Bovy, Nicolas; Kishore, Uday; Robb, Abigail; Katotomichelakis, Michael; Holtappels, Gabriële; Derycke, Lara; Corazza, Francis; Frenckell, R. von; Wathelet, Nathalie; Duchateau, Jean; Legon, Thierry; Pirotton, Sabine; Durham, Stephen R.; Bachert, Claus; Shamji, Mohamed H.

doi:10.1016/j.jaci.2019.02.023

Cited by 42 publications

(39 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For a sustained effect, AIT should be applied for a minimum of 3 years, either continuously or preseasonally 139 . The induction of tolerance by AIT leads to changes in allergen-specific memory T cell and B cell responses and in the allergen-specific IgE and IgG antibody levels, and modifies the activation thresholds for mast cells, basophils and dendritic cells 140 . Of note, the levels of allergen-specific nasal and serum IgG4 antibodies correlate closely with the clinical response to AIT in patients with AR 141 .…”

Section: Allergen-specific Immunotherapymentioning

confidence: 99%

Allergic rhinitis

Bousquet

Antó

Bachert

et al. 2020

Nat Rev Dis Primers

Self Cite

509

385

View full text Add to dashboard Cite

Section: Allergen-specific Immunotherapymentioning

confidence: 99%

Allergic rhinitis

Bousquet

Antó

Bachert

et al. 2020

Nat Rev Dis Primers

Self Cite

509

385

View full text Add to dashboard Cite

“…The study also illustrated that peptide AIT reduces combined symptom and rescue medication scores throughout the pollen season in the active group compared to placebo. Follow‐up mechanistic study demonstrated that the mechanism behind the efficacy of peptide AIT involves immune modulation of T‐ and B‐cell compartments . Whether the efficacy of peptide AIT can also be translated in pediatric subjects remains to be validated.…”

Section: Differences In Mechanistic and Clinical Responses To Allermentioning

confidence: 99%

Allergen Immunotherapy in Children User’s Guide

Alvaro‐Lozano

Akdiş

Alviani

et al. 2020

Pediatric Allergy Immunology

Self Cite

246

240

View full text Add to dashboard Cite

Aim and scopePediatric Allergy and Immunology publishes original contributions and comprehensive reviews related to the understanding and treatment of immune defi ciency, allergic infl ammatory and infectious diseases in children. Other areas of interest include development of specifi c and accessory immunity, and the immunological interaction during pregnancy and lactation between mother and child. As the journal is intended to promote communication between scientists engaged in basic research and clinicians working with children, both clinical and experimental work will be published.

show abstract

“…Around 10% of LPP‐treated patients developed mild early systemic reactions in a 30 minutes of period post‐administration. Finally, a small phase III trial (N = 21) confirmed the benefits from short‐course LPP‐based AIT (more than 50% reduction in combined symptom and rescue medication scores throughout the pollen season) . Immunological mechanisms associated with successful LPP immunotherapy were characterized by the reduction in basophils, seasonal grass pollen‐specific IgE as well as IL‐4 + Th2 cells, the up‐regulation of Foxp3+, follicular regulatory T and IL‐10 + Breg cells together with allergen‐specific IgG4‐blocking antibodies.…”

Section: T Cell Epitope Peptidesmentioning

confidence: 84%

Molecular approaches to allergen‐specific immunotherapy: Are we so far from clinical implementation?

Pechsrichuang

Jacquet

2020

Clin Experimental Allergy

View full text Add to dashboard Cite

Conventional allergen-specific immunotherapy (AIT), based on administrations of allergen extracts, represents up to now the unique protocol for the desensitization of allergic patients. Whereas the effectiveness of AIT was evidenced for the treatment of allergic rhinitis and allergic asthma, such strategy remains experimental for food allergies up to now. However, important issues are commonly associated with AIT as the quality of natural allergen extracts, the long duration and adverse side-effects which negatively affect successful desensitization together with the patient compliance. The rapid progression of molecular allergology made possible the quest of safer, shorter and more effective immunotherapeutic approaches. The aim of this review was to provide an update on these different innovative recombinant derivatives including their efficacy but also their limitations. Despite promising preclinical and early clinical studies, the absence of convincing data in large phase III trials precludes so far the translation of these immunotherapeutic candidates into the clinic. K E Y W O R D S allergen-specific immunotherapy, blocking antibodies, clinical trial, efficacy, hypoallergenic, recombinant derivatives, safety, Treg Present AIT Delivery route SCIT SLIT Molecules Allergen extracts +/-Adjuvant Alum 26Abbreviations: 8x6Q2W, grass allergen peptides at 6 nmol at 2-wk intervals for a total of 8

show abstract

Immunologic mechanisms of a short-course of Lolium perenne peptide immunotherapy: A randomized, double-blind, placebo-controlled trial

Cited by 42 publications

References 44 publications

Allergic rhinitis

Allergic rhinitis

Allergen Immunotherapy in Children User’s Guide

Molecular approaches to allergen‐specific immunotherapy: Are we so far from clinical implementation?

Contact Info

Product

Resources

About